What are CD38-targeting monoclonal antibody drugs?

CD38-targeting monoclonal antibody drugs are pharmacologic agents that share a common mechanism (typically targeting CD38). 2 are currently marketed, with 8 more in clinical development.

What are the marketed CD38-targeting monoclonal antibody drugs?

Marketed CD38-targeting monoclonal antibody drugs include DARATUMUMAB (DARZALEX®), Daratumumab Hyaluronidase-fihj.

CD38-targeting monoclonal antibody

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2 marketed 8 in Phase 3

This page covers all CD38-targeting monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD38.

Targets

CD38

Marketed (2)

DARATUMUMAB (DARZALEX®) · Hospices Civils de Lyon · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.
Daratumumab Hyaluronidase-fihj · Memorial Sloan Kettering Cancer Center · Oncology
Daratumumab binds to CD38 on multiple myeloma cells to trigger their destruction, while hyaluronidase enables faster subcutaneous administration by breaking down hyaluronic acid in tissue.

Phase 3 pipeline (8)

Isatuximab IV · Sanofi · Oncology
Isatuximab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.
Daratumumab SC: daratumumab + rHuPH20 · Janssen Research & Development, LLC · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on multiple myeloma cells and triggers their destruction through multiple immune mechanisms, while rHuPH20 enhances subcutaneous bioavailability.
Daratumumab Injection · Charite University, Berlin, Germany · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on the surface of plasma cells and multiple myeloma cells, triggering their destruction through multiple immune mechanisms.
Dara IV · Janssen Research & Development, LLC · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.
CT-P44(Daratumumab) · Celltrion · Oncology
CT-P44 is a monoclonal antibody that binds to CD38 on multiple myeloma cells, triggering their destruction through antibody-dependent cellular cytotoxicity and direct apoptosis.
Dara SC · Janssen Research & Development, LLC · Oncology
Dara SC (daratumumab subcutaneous) is a monoclonal antibody that targets CD38 on multiple myeloma cells, triggering their destruction through multiple immune mechanisms.
Arm B: Daratumumab Hyaluronidase · PrECOG, LLC. · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on multiple myeloma cells and triggers their destruction through multiple immune mechanisms, while hyaluronidase enables subcutaneous administration by breaking down hyaluronic acid in subcutaneous tissue.
Daratumumab IV · Janssen Research & Development, LLC · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.

Patent intelligence

cd38 targeting monoclonal antibody patent landscape — aggregated cliff calendar, attackable patents, originator estates